Tag Archives: Biotech
By Clark Herman | Published: October 8, 2013
An increasing number of small biotech companies are being hatched to focus on a single disease or condition. The strategy goes against the diversified portfolio approach most big pharma companies have embraced, and instead puts all the eggs in one basket. Dart Therapeutics—one such company—has taken on Duchenne Muscular Dystrophy (DMD), a disease found in [...]
By Clark Herman | Published: September 30, 2013
Since the initial FDA approval of its flagship orphan drug Soliris in 2007, Alexion Pharmaceuticals has done well for itself as a small biotech firm that focuses on ultra-rare disease. So well in fact, that instead of partnering, the company has taken global expansion into its own hands. Apart from a pipeline that includes asfotase [...]
By Guest Blogger | Published: September 27, 2013
By Peter O’ Donnell. Europe’s closest thing to an Oscar’s ceremony for bioscience will take place in early October. The EuropaBio award for the most innovative European Union biotechnology firm is limited to firms with fewer than 250 staff or turnover or balance sheet of less than about $50 million. The aim is to encourage smaller [...]
By Ben Comer | Published: December 13, 2012
Participants in the 23rd Annual NYPF General Assembly last Friday outlined the many challenges facing industry, and the importance of collaboration as a way to move forward.
By Ben Comer | Published: May 7, 2012
The news that Roche scrapped development on its CETP inhibitor dalcetrapib, a drug designed to raise HDL cholesterol in the blood, likely presages the shuttering of Lilly’s development program for its CETP inhibitor, evacetrapib, industry experts and analysts say.